Skip to main content
SpringerLink
Log in

Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine

  • Original Paper
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Down syndrome (DS) patients have an increased risk of developing pulmonary hypertension (PH). Increased plasma levels of asymmetric dimethylarginine (ADMA) may contribute to vascular dysfunction in adults with idiopathic pulmonary hypertension. Our goal was to test the hypothesis that DS patients with PH have higher plasma levels of ADMA than DS patients without PH. DS patients with definitive PH (n = 6) and DS patients with no evidence of PH (n = 12) were studied. Plasma levels of arginine, ADMA, and nitrite/nitrate (NOx; stable metabolites of nitric oxide (NO)) were measured. Plasma arginine concentration was lower (p < 0.05) in PH patients (23 ± 11 μM) versus non-PH patients (46 ± 24 μM). Plasma ADMA concentration was higher (p < 0.005) in PH patients (18.0 ± 4.2 μM) versus non-PH patients (8.6 ± 5.9 μM). Plasma NOx was lower (p < 0.05) in PH patients (4.5 ± 1.7 μM) versus non-PH patients (8.5 ± 7.3 μM). These results are consistent with ADMA contributing to lower NO production in DS patients with PH and suggest that ADMA levels may be a potential biomarker for PH in DS patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. (2009) Proceedings of the 4th World Symposium on Pulmonary Hypertension, February 2008, Dana Point, California, USA. J Am Coll Cardiol 54:S1–117

  2. Beyer J, Kolditz M, Ewert R, Rubens C, Opitz C, Schellong S, Hoeffken G, Halank M (2008) L-arginine plasma levels and severity of idiopathic pulmonary arterial hypertension. Vasa 37:61–67

    Article  PubMed  CAS  Google Scholar 

  3. Boger RH, Mugge A, Bode-Boger SM, Heinzel D, Hoper MM, Frolich JC (1996) Differential systemic and pulmonary hemodynamic effects of L-arginine in patients with coronary artery disease or primary pulmonary hypertension. Int J Clin Pharmacol Ther 34:323–328

    PubMed  CAS  Google Scholar 

  4. Clapp S, Perry BL, Farooki ZQ, Jackson WL, Karpawich PP, Hakimi M, Arciniegas E, Green EW, Pinsky WW (1990) Down’s syndrome, complete atrioventricular canal, and pulmonary vascular obstructive disease. J Thorac Cardiovasc Surg 100:115–121

    PubMed  CAS  Google Scholar 

  5. Cooney TP, Thurlbeck WM (1982) Pulmonary hypoplasia in Down’s syndrome. N Engl J Med 307:1170–1173

    Article  PubMed  CAS  Google Scholar 

  6. Cua CL, Cooke G, Taylor M, Hayes J, Waldon L, Lipowski P, Kossman B, Nash PL (2006) Endothelial nitric oxide synthase polymorphisms associated with abnormal nitric oxide production are not over-represented in children with Down syndrome. Congenit Heart Dis 1:169–174

    Article  PubMed  Google Scholar 

  7. Cua CL, Blankenship A, North AL, Hayes J, Nelin LD (2007) Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates. Pediatr Cardiol 28:250–254

    Article  PubMed  CAS  Google Scholar 

  8. Dimitroulas T, Giannakoulas G, Sfetsios T, Karvounis H, Dimitroula H, Koliakos G, Settas L (2008) Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford) 47:1682–1685

    Article  CAS  Google Scholar 

  9. Durante W, Johnson FK, Johnson RA (2007) Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 34:906–911

    Article  PubMed  CAS  Google Scholar 

  10. Fukushima H, Kosaki K, Sato R, Yagihashi T, Gatayama R, Kodo K, Hayashi T, Nakazawa M, Tsuchihashi T, Maeda J, Kojima Y, Yamagishi H, Takahashi T (2010) Mechanisms underlying early development of pulmonary vascular obstructive disease in Down syndrome: an imbalance in biosynthesis of thromboxane A(2) and prostacyclin. Am J Med Genet A 152A(8):1919–1924

    Article  PubMed  CAS  Google Scholar 

  11. Girard C, Fargnoli JM, Godin-Ribuot D, Dutheil V, Maitrasse B, Girardet P, Arvieux CC (1996) Inhaled nitric oxide: effects on hemodynamics, myocardial contractility, and regional blood flow in dogs with mechanically induced pulmonary artery hypertension. J Heart Lung Transplant 15:700–708

    PubMed  CAS  Google Scholar 

  12. Holm T, Aukrust P, Aagaard E, Ueland T, Haugstad TS, Kjekshus J, Simonsen S, Froland SS, Gullestad L, Andreassen AK (2002) Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: different patterns in heart transplant recipients and individuals with essential hypertension. Transplantation 74:1395–1400

    Article  PubMed  CAS  Google Scholar 

  13. Jin Y, Calvert TJ, Chen B, Chicoine LG, Joshi M, Bauer JA, Liu Y, Nelin LD (2010) Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia. Am J Physiol Heart Circ Physiol 298:H1518–1528

    Article  PubMed  CAS  Google Scholar 

  14. Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, Hoeper MM (2005) Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 25:1414–1418

    Article  PubMed  CAS  Google Scholar 

  15. Komai H, Naito Y, Aimi Y, Kimura H (2001) Nitric oxide synthase expression in lungs of pulmonary hypertensive patients with heart disease. Cardiovasc Pathol 10:29–32

    Article  PubMed  CAS  Google Scholar 

  16. Levine OR, Simpser M (1982) Alveolar hypoventilation and cor pulmonale associated with chronic airway obstruction in infants with Down syndrome. Clin Pediatr (Phila) 21:25–29

    Article  CAS  Google Scholar 

  17. Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C (2005) Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 67:2330–2337

    Article  PubMed  CAS  Google Scholar 

  18. Matsuguma K, Ueda S, Yamagishi S, Matsumoto Y, Kaneyuki U, Shibata R, Fujimura T, Matsuoka H, Kimoto M, Kato S, Imaizumi T, Okuda S (2006) Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 17:2176–2183

    Article  PubMed  CAS  Google Scholar 

  19. McCaffrey MJ, Bose CL, Reiter PD, Stiles AD (1995) Effect of L-arginine infusion on infants with persistent pulmonary hypertension of the newborn. Biol Neonate 67:240–243

    Article  PubMed  CAS  Google Scholar 

  20. McCormack D (1990) Endothelium-derived relaxing factors and the human pulmonary circulation. Lung 168(Suppl):35–42

    Article  PubMed  CAS  Google Scholar 

  21. Millatt LJ, Whitley GS, Li D, Leiper JM, Siragy HM, Carey RM, Johns RA (2003) Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 108:1493–1498

    Article  PubMed  CAS  Google Scholar 

  22. Morris CR, Poljakovic M, Lavrisha L, Machado L, Kuypers FA, Morris SM Jr (2004) Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med 170:148–153

    Article  PubMed  Google Scholar 

  23. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM Jr, Gladwin MT (2005) Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 294:81–90

    Article  PubMed  CAS  Google Scholar 

  24. Nagaya N, Uematsu M, Oya H, Sato N, Sakamaki F, Kyotani S, Ueno K, Nakanishi N, Yamagishi M, Miyatake K (2001) Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med 163:887–891

    PubMed  CAS  Google Scholar 

  25. Pearson DL, Dawling S, Walsh WF, Haines JL, Christman BW, Bazyk A, Scott N, Summar ML (2001) Neonatal pulmonary hypertension—urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. N Engl J Med 344:1832–1838

    Article  PubMed  CAS  Google Scholar 

  26. Pullamsetti S, Kiss L, Ghofrani HA, Voswinckel R, Haredza P, Klepetko W, Aigner C, Fink L, Muyal JP, Weissmann N, Grimminger F, Seeger W, Schermuly RT (2005) Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J 19:1175–1177

    PubMed  CAS  Google Scholar 

  27. Skoro-Sajer N, Mittermayer F, Panzenboeck A, Bonderman D, Sadushi R, Hitsch R, Jakowitsch J, Klepetko W, Kneussl MP, Wolzt M, Lang IM (2007) Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 176:1154–1160

    Article  PubMed  CAS  Google Scholar 

  28. Suzuki K, Yamaki S, Mimori S, Murakami Y, Mori K, Takahashi Y, Kikuchi T (2000) Pulmonary vascular disease in Down’s syndrome with complete atrioventricular septal defect. Am J Cardiol 86:434–437

    Article  PubMed  CAS  Google Scholar 

  29. Tang WH, Wang Z, Cho L, Brennan DM, Hazen SL (2009) Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol 53:2061–2067

    Article  PubMed  CAS  Google Scholar 

  30. Weijerman ME, van Furth AM, van der Mooren MD, van Weissenbruch MM, Rammeloo L, Broers CJ, Gemke RJ (2010) Prevalence of congenital heart defects and persistent pulmonary hypertension of the neonate with Down syndrome. Eur J Pediatr 169(10):1195–1199

    Article  PubMed  Google Scholar 

  31. Yamaki S, Yasui H, Kado H, Yonenaga K, Nakamura Y, Kikuchi T, Ajiki H, Tsunemoto M, Mohri H (1993) Pulmonary vascular disease and operative indications in complete atrioventricular canal defect in early infancy. J Thorac Cardiovasc Surg 106:398–405

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Heart Center, Nationwide Children’s Hospital–The Ohio State University, Columbus, OH, USA

    Clifford L. Cua

  2. Center for Perinatal Research, The Research Institute, Nationwide Children’s Hospital–The Ohio State University, Columbus, OH, USA

    Lynette K. Rogers, Louis G. Chicoine, Molly Augustine, Yi Jin & Leif D. Nelin

  3. Behavioral Pediatrics, Nationwide Children’s Hospital–The Ohio State University, Columbus, OH, USA

    Patricia L. Nash

Authors
  1. Clifford L. Cua
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lynette K. Rogers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Louis G. Chicoine
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Molly Augustine
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yi Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Patricia L. Nash
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Leif D. Nelin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clifford L. Cua.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cua, C.L., Rogers, L.K., Chicoine, L.G. et al. Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine. Eur J Pediatr 170, 859–863 (2011). https://doi.org/10.1007/s00431-010-1361-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-010-1361-x

Keywords

Search

Navigation